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Abstract: Inhibiting Hsp90 chaperone roles using 17AAG induces cytostasis or apoptosis in tumor cells through destabilization of 
several mutated cancer promoting proteins. Although mitochondria are central in deciding the fate of cells, 17AAG induced effects on 
tumor cell mitochondria were largely unknown. Here, we show that Hsp90 inhibition with 17AAG first affects mitochondrial integrity 
in different human tumor cells, neuroblastoma, cervical cancer and glial cells. Using human neuroblastoma tumor cells, we found the 
early effects associated with a change in mitochondrial membrane potential, elongation and engorgement of mitochondria because of 
an increased matrix vacuolization. These effects are specific to Hsp90 inhibition as other chemotherapeutic drugs did not induce similar 
mitochondrial deformity. Further, the effects are independent of oxidative damage and cytoarchitecture destabilization since cytoskel-
etal disruptors and mitochondrial metabolic inhibitors also do not induce similar deformity induced by 17AAG. The 1D PAGE LC MS/
MS mitochondrial proteome analysis of 17AAG treated human neuroblastoma cells showed a loss of 61% proteins from membrane, 
metabolic, chaperone and ribonucleoprotein families. About 31 unmapped protein IDs were identified from proteolytic processing map 
using Swiss-Prot accession number, and converted to the matching gene name searching the ExPASy proteomics server. Our studies 
display that Hsp90 inhibition effects at first embark on mitochondria of tumor cells and compromise mitochondrial integrity.
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Introduction
The Hsp90 protein in association with many tran-
scription factors, signal transduction receptors and 
kinases,  proteins  such  as  actin  and  tubulin  pro-
motes cell survival.1–3  Between  normal  and  tumor 
cells, Hsp90 from tumor cells displays high affinity 
for  binding  and  stabilizing  mutated  oncoproteins. 
  Therefore pharmacological inhibition of Hsp90 using 
anti-Hsp90 drugs such as 17AAG has emerged as a 
novel antitumor strategy to combat cancer. The Hsp90 
inhibition thus destabilizes Hsp90   binding with the 
client  proteins,  which  induces  either    cytostasis  or 
apoptosis.4,5
The  mainstream  of  cancer  treatments  employs 
agents to impede cell division and growth signals. 
Mitochondria are the focal points for a large variety of 
pro- and antiapoptotic stimuli6; therefore play essen-
tial role in the stress-induced cellular   programming.7 
Cancer  cells  are  more  active  than  normal  cells  in 
metabolic  reactive  oxygen  species  (ROS)  genera-
tion and therefore are constantly exposed to oxidative 
stress.8  Neoplastic  lesions  are  also  associated  with 
altered mitochondrial morphology corroborating with 
abnormal mitochondrial energetics, thus deciding the 
fate of tumor initiation, progression and regression.9 
An  association  between  mitochondrial  dysfunction 
and  cancer  has  already  been  reported  by Warburg 
in the early 1930.10 The differences in the molecular 
composition  of  the  mitochondrial  inner  membrane 
between  normal  and  cancer  cells  majorly  encom-
pass the increased levels of cholesterol, varying the 
total phospholipid content and the changes in indi-
vidual  phospholipids.11  These  differences  provided 
information on the sensitivity and stability of tumor 
mitochondria.
Differences between normal cells and cancer cells 
offer the potential for clinical use of mitochondria as 
markers for the detection of cancer and also suggest 
that mitochondria ought to be potential targets for anti-
cancer agents. Pervasively mitochondrial defects play 
important roles in the development and progression 
of cancer,12,13 as a consequence inducing mitochon-
drial dysfunction thought to induce irreversible cell 
damage.14,15 In eukaryotic cells, mitochondria form 
a tubular network,16 and the mitochondrial reticulum 
preserves the mitochondrial topology.17 Shortly, after 
the discovery that mitochondrial membrane poten-
tial (MMP) is often damaged in cancer, mitochondria 
have become the attractive target to induce apoptosis 
and to overcome resistance to chemotherapy.13,18 In 
comparison with the conventional chemotherapeutic 
drugs that aimed at one or two signaling pathways, 
Hsp90 inhibitors inhibit all the six hallmarks of cancer, 
therefore Hsp90 inhibition proposed to act as a com-
binatorial attack on cancer cells.19–21 This increased 
the possibility that Hsp90 inhibitors may also display 
tumor selective targeting of mitochondria.
Mitochondria are morphologically vibrant organ-
elles22; therefore Hsp90 inhibitors may disrupt mito-
chondrial homeostasis in cancer cells. Large portion 
of mitochondrial proteins is not made but imported 
from nuclear coded genes with the help of Hsp90 
and Hsp70 chaperone machines. And any interfer-
ence with either of the chaperone machinery there-
fore  hinders  import  of  mitochondrial  proteins.  In 
support of this speculation, Margineantu et al23 have 
showed  that  Hsp90  inhibitors  induce  accretion  of 
mitochondrial proteins, which was majorly due to the 
decreased mitochondrial protein turnover. There were 
no reports that how Hsp90 inhibition directly affects 
the mitochondria. Given that an early mitochondrial 
changes decide the fate of cells,24 we examined the 
effect of 17AAG on mitochondrial swelling, changes 
in mitochondrial membrane potential and the mito-
chondrial architecture in normal and different human 
tumor cells. From the morphological and proteome 
analysis, we report that 17AAG effectively targets 
tumor cell mitochondria.
Materials and Methods
Materials
17 AAG obtained from invitrogen (Invitrogen, USA). 
Radicicol, cisplatin, novobiocin, rotenone, cyclohex-
imide, cyclosporine A, cobalt chloride, vincristine, 
cytochalasin D, diferuloylmethane, calcium chloride, 
dichlorodihydrofluorescein (DCFDA) procured from 
Sigma (Sigma-Aldrich). The fluorophores, DiOC6(3) 
and JC-1, protonophore CCCP, CMXRos (Mitotracker 
Red), DAPI purchased from Invitrogen- Molecular 
Probes  (Invitrogen).  DMEM  (Dulbecco’s  Modified 
Eagle’s Medium), penicillin, streptomycin and FBS 
(fetal bovine serum) were from Gibco BRL Research 
Laboratories (Gibco-BRL Ltd). The anticytochrome 
c and peroxidase conjugated antirabbit IgG antibody 
purchased  from  (SantaCruz),  Chemilumeniscence 
western blotting kit purchased from Roche.17AAg induces mitochondrial deformity
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Isolation of mitochondria from rat liver
Freshly excised rat liver from male Wistar rat was 
minced in a Dounce homogenizer with pestle in a 
sucrose buffer (20 mM mannitol, 70 mM sucrose, 
1 mM EGTA, 10 mM Hepes and 1x protease cock-
tail) to single suspension and subjected to differ-
ential  centrifugation.  The  mitochondria  isolated 
by modified differential centrifugation procedure, 
homogenized sample centrifuged at 1000  g for 
10 min at 4 °C, supernatant collected and recentri-
fuged at 12000  g for 15 min. The pellet consid-
ered as crude mitochondrial fraction, optical density 
measured  at  590  nm,  confirmed  with  immunob-
lot with anticox IV antibody, and used for ex vivo 
mitochondrial  swelling  experiments. All  the  ani-
mal experiments were carried out according to the 
institutional standards approved by the institutional 
ethical committee.
cell cultures and treatments
Human neuroblastoma cells- IMR-32, human cer-
vical  cancer-  HeLa,  human  glioblastoma  cells- 
HNGC2, human liver cancer cells- HepG2 obtained 
from American Type Cell Culture (ATCC). Cells 
maintained in DMEM containing 10% FBS in the 
presence of penicillin (100 U/ml) and streptomy-
cin (50 µg/ml) at 37 °C in a humidified incubator 
with 5% CO2 supply. For treatments, 1  105 cells 
grown on cover glass (22  22 mm, Fisher Scien-
tifics) in a 6-well culture dish (Nunc) incubated in 
complete medium with the drug at different time 
intervals.  Different  concentrations  of  17AAG 
(0.5 µM–10 µM) tested with tumor cells and the 
effective drug concentration standardized by ana-
lyzing its ability to degrade 80% Hsp90 client pro-
tein, Raf-1. Other drug concentrations standardized 
by cytotoxicity or cell cycle inhibition using trypan 
blue exclusion or Fluorescence Activated Cell Sort-
ing (FACS) of propidium iodide (PI) stained cells 
respectively. The stock solutions of drugs 17AAG, 
radicicol,  cisplatin,  paclitaxel,  diferuloylmethane, 
rotenone, cyclosporine A and cytochalasin D were 
prepared  in  dimethylsulfoxide.  The  vincristine, 
cobalt chloride, novobiocin, calcium chloride and 
digitonin were prepared in double distilled sterile 
water. Hydrogen peroxide (H2O2) was diluted and 
used either in the culture medium or buffer directly 
from the stock.
Subcellular fractionation of mitochondria 
from tumor cells
Briefly, normal and tumor cells were washed with 
PBS, and resuspended in isotonic buffer A (20 mM 
mannitol,  7  mM  sucrose,  1  mM  EGTA,  10  mM 
HEPES, pH 7.5), supplemented with protease inhibi-
tors  (1  mM  phenylmethylsulfonyl  fluoride;  PMSF, 
10 µg/mL leupeptin, 10 µg/mL pepstatin A, 10 µg/mL 
  soybean trypsin inhibitor, and 10 µg/mL aprotinin), 
and homogenized gently using Dounce glass homog-
enizer with 40 strokes. The sample was centrifuged 
at 3500 rpm for 10 min and the supernatant was col-
lected and recentrifuged at 12,000 rpm for 10 min 
(Sorval 5B, SS34 rotor). The pellet containing the 
mitochondria was suspended in a buffer (400 mM 
mannitol,  50  mM Tris.Cl,  pH  7.2,  5  mg/ml  BSA, 
10 mM KH2PO4) and used for further experiments.
Monitoring the ex vivo swelling  
of mitochondria
The isolated mitochondria (0.5 mg/ml) from normal 
rat liver and human neuroblastoma cells were incu-
bated in a KCl-based buffer (150 mM KCl, 25 mM 
NaHCO3, 1 mM MgCl2, 1 mM KH2PO4, 20 mM Hepes, 
1 mM Glutamate and 1 mM Malate, pH 7.4). Mito-
chondrial swelling was measured as a decrease in the 
optical density at 520 nm using a split beam spectro-
photometer (Perkin-Elmer, Cetus). The mitochondrial 
swelling was induced with 150 µM Ca2+ and 0.1 mM 
inorganic phosphate. For recovery, 100 µM CsA was 
added to the reaction mixture. The absorbance was 
measured for 30 min with each treatment and the val-
ues obtained were converted to percentages.
cytochrome c assay
The cytochrome c assay was performed colorimetri-
cally by cytochrome c reduction using potassium fer-
ricyanide [K3Fe(CN)6]. The conversion of heme ions 
from Fe3+ to Fe2+ was monitored by adding sodium 
hydrosulfide (Na2S2O4). The difference in oxidized 
and reduced cytochrome c was measured at 550 nm 
and 542 nm respectively. The cytochrome c release 
was calculated using the following formula,
cytochromec mM
AAAA RROR
RO
[]
=
−+−
∆
×
−
550 542 542 550
550
() () () ()
()
di ilutionVishal et al
14  Drug Target Insights 2011:5
The cytochrome c values represented in the bar 
diagram were normalized with control and expressed 
in percentages.
Measurement of change in mitochondrial   
membrane potential (∆Ψm)
The ∆Ψm quantified by flow cytometric analysis of 
cells stained with JC-1. Cells after respective drug 
treatments were incubated with 40 nM of JC-1 in the 
presence or absence of 50 µM CCCP for 15 min at 
37 °C. The fluorescence was measured by fluores-
cence activated cell sorter (MoFlo, Becton-Dikinson, 
SanJose, CA) and analyzed using Cell-Quest software. 
The values obtained as ratio between dual florescence 
red versus green was measured and normalized with 
control fluorescence. Similarly for some experiments, 
DiOC6(3) was employed to measure the change in 
the membrane potential. A decrease in green flores-
cence indicated as a change in the membrane poten-
tial. The values obtained were converted to percent 
change and represented in a bar diagram.
Transmission electron microscopy (TeM)
Cells untreated and drug treated were fixed with 5% 
glutaraldehyde solution in 0.1 M sodium cacodylate 
buffer  (pH  7.4)  and  post  fixed  using  1%  osmium 
tetroxide in 0.1 M sodium cacodylate buffer. Cells 
washed with 0.1 M potassium phosphate buffer, pH 
7.4, and dehydrated with increasing acetone concen-
trations (30%, 50%, 70%, 90% and 100%). First the 
cells were treated with propylene oxide and polymer-
ized with araldite resin (1:1 ratio) in silicon moulds. 
Cells were sectioned using Reichert Ultracut-S ultra-
microtome, thin sections (80 nm) placed on copper 
grids,  washed  with  sterile  double  distilled  water, 
stained  with  Uranyl  acetate  (2%)  for  30  min  and 
observed with a JEOL transmission electron micro-
scope (Model JEM-2010, Tokyo, Japan).
Laser scanning confocal microscopy
Untreated  and  treated  cells  were  incubated  in  a 
medium containing 50 nM of MitoTracker Red for 
30 min at culture conditions. Cells were washed and 
fixed with 4% paraformaldehyde for 15 min, and per-
meabilized with 0.1% Triton X-100 for each 10 min. 
The cover glasses after PBS wash were mounted on to 
the glass slides with ProLong Antifade reagent con-
taining DAPI (50 nM, Invitrogen), sealed with nail 
polish and observed using laser scanning confocal 
microscopy (Leica TCS SP5).
reactive oxygen species (rOS) 
measurements by flow cytometry 
analysis (FAcS)
The untreated and 17AAG treated cells for 6 h, 12 h, 
and 24 h intervals were first washed with PBS, incu-
bated  with  2  µM  2′-7′-dichlorofluorescin  diacetate 
(DCFDA) for 15 min, 37 °C in the dark. The dye 
DCFDA can passively diffuse into cells and is colorless 
and nonfluorescent until the acetate groups are cleaved 
by intracellular esterases to yield the fluorescent fluo-
rophore, 5-(and-6)-carboxy-2′,7′ -dichlorofluorescein 
(DCF). The cells were washed twice with PBS and 
the intensity of DCF fluorescence was measured by 
FACS (FACS Calibur).
gel electrophoresis and in-gel digestion 
for 1D PAge Lc- MS/MS
For each 1D PAGE LC-MS/MS experiments 40 µg 
of the mitochondrial preparation from untreated and 
drug treated cells (9  107) fractionated on a 12% 
SDS-PAGE. The gels were stained with Coomassie 
Brilliant  Blue  (R250)  for  one  hour,  destained  and 
washed with MilliQ water several times. Each gel 
lane was sliced and washed 3 times for 30 min each 
in 50% Acetonitrile (ACN) with 25 mM Ammonium 
Bicarbonate (ABC, pH 8.0) to remove excess Coo-
massie stain, followed by one wash with 50% ACN, 
and the final wash with 100% ACN without bicarbon-
ate buffer each for 5 min to dehydrate the gels. Excess 
ACN was removed and the gel slices were vacuum 
dried for 30 min. The dried gels were rehydrated and 
trypsinized with 30 µl cold Trypsin (Promega) solu-
tion (10 µg/ml in 25 mM ABC pH 8.0) and incubated 
at 37 °C for 16 h. The tryptic peptides were extracted 
by soaking the gel slices in 50 µl of 50% ACN and 
5% trifluoroacetic acid (TFA) for 60 min with gentle 
agitation at room temperature. The supernatant was 
collected and transferred to a second clean microfuge 
tube.  The  gels  were  extracted  again  with  another 
50 µl aliquot of 50% ACN and 5% TFA for 60 min. 
The two extracts were pooled and vacuum dried to 
complete  dryness  for  one  hour. The  samples  were 
reconstituted in 12 µl of 5% ACN and 0.1% TFA and 
loaded on SDS-PAGE.17AAg induces mitochondrial deformity
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1D PAge Lc-MS/MS analysis
All  1D  LC-MS/MS  experiments  were  carried  out 
using  ESI-  mass  spectrometer  with  linear  ion  trap 
mass  analyzer  (LTQ-IT; Thermo  Fischer, Waltham, 
MA,  USA),  equipped  with  Finnigan  Surveyor  MS 
Pump Plus. The sample (10 µl) was loaded with con-
stant flow of 2 µl/min onto a reverse phase Micro LC 
column BioBasic C18 (ThermoFisher, Waltham, MA, 
USA). Peptides eluted on a gradient of 90 min for each 
gel slice starting with 95% water, 5% ACN, 0.1% TFA 
for the first 20 min in which 10 min were for retention 
of peptides in the sample buffer. Acetonitrile gradient 
was set from 5%–95% over the next 70 min followed 
by 95% water wash for the last 10 min. Chromato-
graphically separated peptides were sprayed through a 
20 cm metal needle emitter and the mass spectrometer 
ran in the data-dependent mode to gain MS and MS/
MS spectrums switching automatically between MS 
and MS/MS modes. One full MS scan from 200 to 
2000 m/z was followed by 7 data-dependent MS/MS 
scans recorded. The electrospray voltage was set at 
4.5 kV, and capillary temperature at 200 °C. The pep-
tides fragmented using CID with normalized collision 
energy of 35%. Top 7 precursor ions were selected for 
MS/MS analysis. The raw files picked up were com-
piled and subjected to bioinformatics analysis.
Bioinformatics analysis
The  mass  spectrums  searched  against  the  protein 
sequences  of  the  IPI  human  database  (version  37) 
from NCBI using SEQUEST algorithm were incor-
porated in the BioWorks Browser (Version 3.2 EF2, 
Thermo  Electron  Corporation.).  Enzyme  specificity 
was set to full trypsin digestion with only one missed 
cleavage. Methionine oxidation was set as a variable 
  modification. The other parameters were set as fol-
lows: precursor ion tolerance as 1 amu and fragment 
ion tolerance as 0.35 amu. Peptide identification was 
accepted if they passed the filter set to delta CN value 
as 0.100, Rsp as 5, Xcorr vs charge values as 1.90 (+1 
charge), 2.20 (+2 charge) and 3.30 (+3 charge) and pro-
tein probability as 0.001. Protein identifications were 
accepted only if they contained at least one unique 
peptide (from untreated and 17AAG treatments).
Statistical analysis of the data
Data represented as SE ± mean. The control groups 
were  compared  with  drug  treated  group  and  the 
  significance value was calculated by paired student’s 
t-test using SigmaPlot 11 software. A p value , 0.05 
was accepted as significant.
Results
17AAg treatment induces ex vivo 
mitochondrial swelling
17AAG selectively binds to the N-terminal ATP-bind-
ing region of Hsp90, therefore competes with ATP for 
binding. In tumor cells, Hsp90 exists in a high affinity 
conformation therefore compared to normal cells it 
displays a 100-fold higher affinity towards 17AAG 
binding.25 Mitochondrion swelling is a hallmark of 
mitochondrial  dysfunction.26  Isolated  mitochondria 
undergo  swelling  because  of  opening  nonselective 
permeability transition (PT) with uptake of water and 
solutes  when  exposed  to  various  uncouplers.27  PT 
pores have two open conductance states, after low-
level of induction regulated PT pores opened by Ca2+ 
can be blocked by CsA, but after higher levels of 
induction unregulated PT pores are Ca2+ independent 
and CsA insensitive.28
Many  chemotherapeutic  drugs  are  known  for 
opening of PT pores, and CsA inhibits PT pore open-
ing induced by such drugs. We wanted to test whether 
17AAG has any effect on PT pore opening, if so, we 
wanted to examine whether it is CsA dependent or 
independent.  Towards  this,  the  isolated  mitochon-
dria from normal and tumor cells were examined for 
ex  vivo  mitochondrial  swelling  either  with  10  µM 
17AAG or 150 µM calcium for 30 min in the pres-
ence  and  absence  of  CsA.  Normal  mitochondria 
treated with Ca2+ showed 84% swelling and a 63.3% 
recovery with CsA, while 17AAG treatment showed 
31% swelling and the CsA treatment reversed 17AAG 
induced swelling only by 25.7% (Fig. 1A, P , 0.001). 
In human neuroblastoma, the ex vivo mitochondrial 
swelling observed with Ca2+ was 86.2% and with 2 µM 
17AAG it was found to be 66.4%, which was almost 
double to 17AAG induced mitochondrial swelling in 
normal cells. Between 17AAG and Ca2+, Ca2+ treated 
cells  showed  55.3%  recovery  with  CsA  and  with 
17AAG  treatment  there  was  only  22.7%  recovery 
(Fig. 1B, P , 0.001). Since primary cell mitochon-
dria used in the present study arose from liver cells, 
human hepatocellular carcinoma cells were used to 
study the drug effects.   Similar to the results obtained 
with human neuroblastoma, in   hepatocarcinoma cells, Vishal et al
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while Ca2+ induced swelling recovered by cyclosporine 
A, 17AAG induced swelling showed only a slight 
recovery (Fig. 1C, P , 0.001). These findings sug-
gested that 17AAG undeniably is responsible for the 
irreversible  mitochondrial  swelling  in  tumor  cells. 
Since 17AAG induced effects on mitochondria were 
specific to tumor cells, we used only human neuro-
blastoma tumor cells for later experiments.
To understand whether ex vivo mitochondrial swell-
ing  correlates  with  mitochondrial  damage  through 
cytochrome c release,29 cytochrome c reduction assay 
was performed after 2 h incubation of mitochondria 
with 10 µM 17AAG, 150 µM Ca2+. The assay was 
performed  using  potassium  ferricyanide  reduction 
from separating the supernatant and pellet fractions 
of  mitochondria  after  centrifugation  at  4000  rpm 
for 15 minutes. Calcium induced an extra 1.6-fold 
(P , 0.01) and 17AAG induced 6.6-fold (P , 0.001) 
cytochrome c release from the mitochondria of tumor 
cells was compared to the mitochondria from nor-
mal cells (Fig. 1D). To study the effect of 17AAG on 
mitochondria integrity, IMR-32 cells were examined 
for  cytochrome  c  release  with    different  anticancer 
agents like diferuloylmethane, vincristine, cytochala-
sin D and hydrogen peroxide for 8 h in comparison 
with cells treated with 2 µM 17AAG. After respec-
tive drug treatments, the mitochondria and cytosolic 
fractions  were  separated  and  immunoblotted  with 
anticytochrome c antibody. While diferuloylmethane, 
vinscristine and 17AAG showed retention of cyto-
chrome c in the mitochondria, H2O2 treatment dam-
aged  mitochondria,  as  measured  by  the  release  of 
cytochrome c (Fig. 1E).
17AAg treatment induces change  
in mitochondrial membrane potential  
(∆Ψm)
The mitochondrial membrane potential is a biomarker 
for  mitochondrial  damage.30  To  examine  whether 
17AAG treatment induces any change in ∆Ψm, using 
a lipophilic cationic dye JC-1, we measured ∆Ψm by 
FACS.  Under  normal  physiological  conditions,  in 
healthy cells, the JC-1 dye stains the mitochondria 
bright red. The negative charge found out by the intact 
mitochondrial membrane potential allows the lipo-
philic dye, bearing a delocalized positive charge, to 
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enter the mitochondrial matrix where it accumulates. 
The JC-1 dye aggregates in the mitochondria and the 
aggregates  fluoresce  red.  When  the  mitochondrial 
membrane potential collapses, the JC-1 dye cannot 
accumulate  in  the  mitochondria,  therefore  remains 
in the cytoplasm in a green fluorescent monomeric 
form. A decrease in the red/green fluorescence ratio 
was  measured  after  2  µM  17AAG  treatment.  We 
employed protonophore CCCP as a positive control 
to induce ∆Ψm (Fig. 2A). 17AAG treatment showed 
a decrease in membrane potential by 28.82% in a 6 h 
treatment,  which  subsequently  lowered  to  10.12% 
by 12 h treatment and increased to 18.32% by 24 h 
treatment (Fig. 2B, P , 0.001) suggested the 17AAG 
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12 h and 24 h intervals of incubation. B) Statistical representation of FAcS data. cccP employed as a positive control to induce ∆Ψm change.Vishal et al
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induced mitochondria changes observed as early by 
6 h treatment.
effect of 17AAg and other hsp90 
inhibitors on mitochondrial deformity
Though the molecular basis of mitochondrial polar-
ization is well explained by the chemiosmotic theory, 
it is also influenced by the intracellular and extra-
cellular  environments.31  Besides  intracellular  and 
extracellular environments, a control over cell shape 
and size can also determine mitochondria integrity.32 
Therefore we recorded mitoarchitectural changes in 
IMR-32  cells  on  17AAG  treatment  by  laser  scan-
ning  confocal  microscopy,  and  saw  mitochondrial 
deformity  associated  with  mitochondria  elongation 
in  time-dependent  manner  (Fig.  3A).  To  explain 
the cell type specific effects of 17AAG, HeLa and 
HNGC2  cells  were  also  treated  with  17AAG  and 
examined  for  mitochondrial  changes. We  followed 
17AAG   treatment induced elongation of mitochon-
dria in both the cells types (Fig. 3B and 3C), implying 
the significance of Hsp90 inhibition in tumor cells in 
mitochondria targeting.
Several  groups  of  Hsp90  inhibitor  drugs  were 
developed and set for preclinical evaluation. Among 
them,  radicicol,  cisplatin  and  novobiocin  that  are 
structurally unrelated to 17AAG but shown to inhibit 
Hsp90. Radicicol is a macrolactone antibiotic known 
to bind to the N-terminal domain of Hsp90.33 Cispla-
tin is a platinum-based chemotherapeutic drug that 
binds both N- and C-terminal domains of Hsp90.34 
Novobiocin is aminocoumarin antibiotic that can spe-
cifically binds to Hsp90 at the C-terminal nucleotide 
binding  pocket.35  The  neuroblastoma  tumor  cells 
were treated with 2 µM concentrations of radicicol 
and cisplatin, 0.1 mM concentrations of novobiocin 
for 8 h, and after staining with CMXRos cells were 
analyzed using laser scanning confocal microscope. 
To compare Hsp90 inhibition effects on mitochon-
dria, nonHsp90 drugs, paclitaxel and vincristine were 
used at a concentration of 5 µM each at similar exper-
imental conditions. In support of the data we obtained 
from 17AAG treatments in Figure 3, we noted simi-
lar  mitochondria  elongation  effects  with  radicicol, 
cisplatin, and novobiocin, but not with paclitaxel and 
vincristine as the latter treatments induced formation 
of circular mitochondria (Fig. 4 A).
From  the  previous  results,  we  did  not  get  any 
  information whether Hsp90 inhibition is inducing met-
abolic block or merely altering the   mitoarchitecture. 
Usually, mitochondrial changes reported when mito-
chondrial protein turnover blocked36 or on mitochon-
drial dysfunction.37 To understand mitoacrhitectural 
effects  of  17AAG,  we  examined  mitochondria  of 
IMR-32  cells  with  metabolic  inhibitors,  rotenone38 
and cycloheximide,39 and ROS inducers diferuloyl-
methane40  and  cobalt  chloride.41  We  noted  all  the 
treatments resulting in forming spherical, giant mito-
chondria surrounding the nucleus (Fig. 4B), suggest-
ing 17AAG induced mitoarchitectural changes may 
be independent of metabolic stress.
effect of 17AAg on digitonin 
permeabilization
There were reports that digitonin combination with anti-
cancer agents improves drug intake and increases anti-
cancer effects.42 Digitonin selectively disrupts the lipid 
membranes  enriched  in  sterols.  Digitonin  complexes 
with unesterified 3-β-hydroxysterols including choles-
terol and promotes to disrupt cholesterol-rich cellular 
membranes.  Mitochondrial  membrane  also  contains 
large amounts of cholesterol and can easily be disrupted 
by digitonin. However, in case of isolated mitochondria, 
digitonin causes nonspecific effects such as release of 
cytochrome c and Ca2+, 43 and at higher concentrations 
such as 48 µM and 64 µM it causes similar changes.44 
Therefore in the present study, we have used 8 µM con-
centration of digitonin and this concentration is standard-
ized in such a way that it should not affect mitochondrial 
integrity. Digitonin was used to promote 17AAG import 
to mitochondria and to study its mitochondria selective 
effects. A permeabilization of IMR-32 cells with digi-
tonin (30 min) concentrations before 17AAG treatment 
neither resulted in elongation nor spherical formation of 
mitochondria, but induced apoptosis by 12 h (Fig. 5A) 
and on prolonged treatments (by 24 h treatment) cells 
were found unviable. Apoptosis activation has corre-
lated with significant changes in ∆Ψm and cytochrome 
c release (Fig. 5B and 5C).
effect of reactive oxygen species (rOS) 
on early mitochondrial deformity
A  gradual  increase  in  mitochondrial  depolariza-
tion  in  our  study  suggested  a  possible  increase  in 17AAg induces mitochondrial deformity
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Figure 3. 17AAg induced changes in mitochondrial morphology. A) control and drug treated IMr-32 cells (6 h, 12 h and 24 h intervals) stained with 
cMXRos and DAPI pictured at 63, scale bar (-) represents 25 microns. note a change in mitochondria morphology. B) Analysis of mitochondria mor-
phology of heLa cells. c) Analysis of mitochondria morphology of HNGC2 cells. Note both HeLa and HNGC2 cells change their morphology specifically 
resulting in mitochondria elongation after 17AAg treatment. Both cell types analyzed using 63 x objectives and the scale bar (-) represents 25 microns.
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Figure 4. Analysis of mitochondrial morphology with metabolic inhibitor drugs. A) cells treated with different hsp90 inhibitors and compared with cytoskel-
etal disruptor for mitochondrial effects. B) cells treated with different mitochondrial metabolic inhibitors and chemotherapeutic agents. After respective 
drug treatments, cells treated with cMXRos and the mitochondria viewed under laser scanning confocal microscope (63; scale bar (-) represents 
25 microns). note that drug treatments resulted in spherical and desolated mitochondria gathered border to the nuclear membrane.
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the    intracellular  reactive  oxygen  species  (ROS)41. 
  Therefore  we  measured  intracellular  ROS  levels 
using  fluorophore  DCFDA  that  passively  diffuses 
into cells. The dye, DCFDA is colorless and non-
fluorescent until the acetate groups are cleaved by 
intracellular esterases to yield the dichlorofluorescein 
(DCFH). The resulting DCFH reacts with ROS and 
forms dichlorodihydrofluorescein (DCF). An increase 
in  DCF  fluorescence  is  an  indicative  of  increased 
cellular oxidation because of increased intracellular 
ROS measured. We saw a moderate increase in ROS 
levels with 17AAG treatment and especially at 6 h 
it is negligible (Fig. 6A). A gradual increase in ROS 
levels by 12 h and 24 h treatments may relate to mito-
chondrial signaling, functional blocking, thus result-
ing in damage to mitochondria. We also measured 
mitochondrial membrane integrity using DiOC6(3) by 
FACS in the presence and absence of ROS scavenger, 
N-acetyl cysteine (NAC, 1 mM), in combination with 
17AAG (2 µM). Hydrogen peroxide (H2O2, 50 µM, 
45 min) was used as a positive control to induce ROS. 
We noted a decrease in H2O2 induced negative change 
in mitochondrial membrane potential in combination 
with NAC but not with 17AAG combination suggest-
ing that 17AAG induced effects may be independent 
of ROS (Fig. 6B).
17AAg induced changes are because  
of increased elongation
To  further  confirm  17AAG  induced  mitochondrial 
elongation,  laser  scanning  confocal  images  were 
subjected to morphometric analysis using the soft-
ware provided with the Leica TCS SP5 microscope. 
Individual mitochondria were randomly painted with 
different  colors  and  then  each  mitochondrion  was 
measured (Fig. 7A, n = 60). We noted 81% and 118% 
increase  in  the  mitochondria  length  after  17AAG 
treatment for 6 h and 12 h intervals respectively com-
pared to untreated mitochondria. In a 24 h treatment, 
we saw 21% decrease in the length compared to con-
trol (Fig. 7B, P , 0.05). An increase in ROS levels 
by 24 h 17AAG treatment (Fig. 6A) may be playing 
a role in decreasing the mitochondrial elongation by 
affecting its role.
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Figure 5. A) Analysis of mitochondria morphology after digitonin sensitization to 17AAg treatment. IMr-32 cells at different intervals of treatment stained 
for mitochondria and analyzed by laser scanning confocal imaging microscope (63; scale bar (-) represents 25 microns). note appearance of apoptotic 
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and cytosol fractions and examined for the presence of cytochrome c by cytochrome c reduction assay. note digitonin treatment with 17AAg inducing the 
cytochrome c release.Vishal et al
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17AAg treatment induces vacuolization 
and engorgement of mitochondria
To  gain  ultrastructural  details  of  mitochondrion, 
TEM  analysis  was  performed  on  17AAG  treated 
IMR-32  cells.  From  the  electron  micrographs  we 
noted a time-dependent increase in both elongation 
and  vacuolization  of  mitochondria  after  the  drug 
treatment (Fig. 8A). To get statistical value from the 
electron  micrographs,  TEM  images  from  different 
experiments were analyzed using ‘Gatan software’, 
and measured the length and thickness of individ-
ual mitochondrion. A representative bar diagram of 
mitochondrial  length  and  thickness  comparing  the 
control (n = 20) and 17AAG treatment (n = 24) cells 
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Figure 6. A) Intracellular rOS measurement after 17AAg treatment. IMr-32 cells after respective drug treatments incubated with DcFDA for 20 min and 
the DCF fluorescence measured by FACS. B) effect of rOS on mitochondrial membrane potential. IMr-32 cells treated with 17AAg for 24 h with and 
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was plotted. A 4 h treatment resulted in a significant 
increase in mitochondrial length by 12% (P , 0.001) 
and thickness by 18% (P , 0.01), a 6 h treatment 
increased the length by 106% and thickness by 81% 
(P , 0.001). However, by 8 h of 17AAG treatment 
the  length  increased  by  263%  while  the  thickness 
showed only 85% (P , 0.001) increase (Fig. 8B).
Mitochondrial proteome of human 
neuroblastoma cells
The  2-DE  is  an  extensively  used  method  for  pro-
teome  analysis;  however,  this  approach  provides 
information  on  total  cell  proteome.  Our  2-DE  of 
control IMR-32 cells gave 238 ± 3 (P , 0.001) and 
17AAG treatment gave 195 ± 10 (P , 0.001) spots 
when counted on a CBB stained 2-DE gel. The results 
show that 17AAG treatment induces only 19% loss of 
total cellular proteins (data not presented). Since the 
total cell lysate contains majority of cytoplasmic and 
nuclear proteins, to enrich mitochondrial proteins in 
our study, we adapted 1D PAGE LC MS/MS   analysis. 
The 1D PAGE LC MS/MS was majorly used for the 
analysis of low complex mixture of proteins sepa-
rated by gel electrophoresis or treated as a mixture. 
  Mitochondria preparations were examined for purity 
since  several  reports  stated  that  the  mitochondrial 
preparations  contained  cytoplasmic    contamination. 
The mitochondrial purity was assessed by dot blot 
analysis  of  mitochondrial  proteins,  cox  IV  and 
  mortalin (Fig. 9).
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Figure 8. Transmission electron microscopic analysis of mitochondria. 
A) control and 17AAg treated IMr-32 cells at different intervals (2 h, 
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B) TeM images analyzed using gatan software to measure the length 
(L) and width (W) of individual mitochondria where control and DMSO 
values normalized. The statistical representation of mitochondrial width 
and length earned from three individual experiments.Vishal et al
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Annotated  MS/MS  spectrums  from  five  inde-
pendent  experiments  was  compiled  averaging  to 
927,54 spectrums in the control and 878,98 spectrums 
in the 17AAG treatment used for the present analysis. 
The molecular, biological and cellular component for 
each protein was assigned based on Gene Ontology 
(GO) classification45. The homologues of each pro-
tein were searched in NCBI Homologue database.46
From the analysis, we found that from the control 
cells, out of 171 proteins, 119 were identified by at 
least one unique peptide sequence signature as mito-
chondrial proteins. Single peptide PMF identification 
and annotated spectrums are provided for each protein 
(Supplemental Fig. 1). A list of proteins that was iden-
tified from the analysis is enclosed as   supplementary 
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Mitochondria
Cytosol
Control
COX IV Mortalin Input
17AAG
Figure 9. Confirmation of mitochondria purity by immunoblot analysis 
using dot blot technique. Five micrograms of protein used for spotting. 
Mitochondria marker proteins anticox IV and antimortalin antibodies were 
used for immunoblot analysis. The input represents equal loading of total 
proteins from Ponceau-S stained nc paper.
information with right protein ID, Gene ID and pro-
tein with respective peptide sequence (Table 1). The 
17AAG treatment identified only 67 proteins with at 
least one unique peptide sequence. The IDs got by 
1D PAGE LC MS/MS were filed to PRIDE database 
(www.ebi.ac.uk/pride) with the accession numbers, 
control: 12861–12870 and 17AAG treatment: 13646–
13650. From the primary assessment itself we found 
that 8 h 17AAG treatment resulted in loss of 61% pro-
teins (Table 1). The major classes that emerged from 
this analysis were chaperones (11.76%), Ras family 
of proteins (6.72%), metabolic enzymes that included 
mitochondria, membrane and oxidative phosphoryla-
tion related (48.74%), cytoskeletal proteins (6.72%), 
ribosomal proteins (16.81%) and chromatin related 
proteins (9.24%). The presence of cytoskeletal pro-
teins  such  as  actin  and  actin-related  proteins  rein-
forces that mitochondria are tightly   associated with 
cytoskeletal proteins. Hsp90 inhibition would have 
affected  extramitochondrial  roles  such  as  import 
and several signaling events and further loss of sev-
eral metabolic enzymes suggests functionally com-
promised mitochondria. The loss of DNA and RNA 
metabolism suggested the turn down of mitochon-
drial transcription and translation.
We have identified 16.8% proteins unmapped but 
down-regulated  and  9.24%  proteins  up-regulated 
by 17AAG treatment. The down-regulated proteins 
were majorly from oxidative phosphorylation, actin 
family of proteins and transcription-translation pro-
Table 1. Peptide and protein identification in a comparative table format between control and 17AAG treated IMR-32 cells. The num-
bers under control and 17AAg treatment shows the number of peptides matched with the represented protein ID in our screening.
DnA/RnA metabolism
ID control 17AAG Gene Function
IPI00008524 1 – PABPc1 poly(A) binding protein, cytoplasmic 1 mrnA metabolism
IPI000D9328 1 – eIF4-A3 eukaryotic translation initiation factor 4A3 translation initiation
IPI00014424 2 1 eeF1A2 eukaryotic translation elongation factor  
1 alpha 2
Protein biosynthesis
IPI00017334 9 – PhB prohibitin Inhibits DnA synthesis
IPI00018278 2 – h2AFV h2A histone family, member V histones
IFI00026272 1 – hIST1h2Ae histone cluster 1, h2ae histone cluster
IPI00027107 2 1 TUFM Tu translation elongation factor, mitochondrial Protein biosynthesis
IPI00027252 10 – PhB2 prohibitin 2 transcriptional repressor
IPI00029744 3 – SSBP1 single-stranded DnA binding protein 1 DnA replication
IPI00220740 – 1 nPM1 nucleophosmin (nucleolar phosphoprotein  
B23, numatrin)
chromatin regulation
IPI00783271 1 – LrPPrc leucine-rich PPr-motif containing rnA metabolism
(Continued)17AAg induces mitochondrial deformity
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Table 1. (Continued)
ID control 17AAG Gene Function
cytoskeletal proteins
IPI00013508 3 – AcTn1 actinin, alpha 1 F-actin cross linking 
potein
IPI00013808 5 1 AcTn4 actinin, alpha 4 F-actin cross linking 
protein
IPI00016334 1 – McAM melanoma cell adhesion molecule 
[homo sapiens]
adhesion molecule
IPI00019157 12 2 cSPg4 chondroitin sulfate proteoglycan 4 proteoglycan
IPI00021439 4 2 AcTB actin, beta actin
IPI00215948 1 – cTnnA1 catenin (cadherin-associated protein), alpha 
1,102kDa
cell adhesion
IPI00328715 1 – MTDh metadherin adhesion molecule
IPI00334190 – 1 STOML2 stomatin (ePB72)-like cytoskeletal associate
Oncogenes
IPI00007755 1 – rAB21 rAB21, member rAS oncogene family ras oncogenes
IPI00016339 1 – rAB5c rAB5c, member rAS oncogene family
IPI00016342 7 – rAB7A rAB7A, member rAS oncogene family
IPI0001e373 2 – rAB13 rAB13, member rAS oncogene family
IPI00020436 3 – rAB11B rAB11B, member rAS oncogene family
IPI00030304 rAB6c rAB6c, member rAS oncogene family
IPI00031169 2 – rAB2A rAB2A, member rAS oncogene family
IPI00300096 1 – rAB35 rAB35, member rAS oncogene family
Molecular chaperones
IPI00003362 13 1 hSPA5 heat shock 70kDa protein 5  
(glucose-regulated protein, 78kDa)
chaperone
IPI00003865 6 4 hSPAB heat shock 70kDa protein 8 chaperone
IPI00007765 2 1 hSPA9 heat shock 70kDa protein 9 (mortalin) chaperone and 
senescence marker
IPI00018465 – 1 ccT7 chaperonin containing TcP1, subunit 7 (eta) cytosolic chaperone
IPI00020599 5 1 cALr calreticulin calcium binding 
chaperone
IPI00027230 10 1 hSP90B1 heat shock protein 90kDa beta(grp94),  
member 1
glucose regulated 
chaperone
IPI00030275 – 1 TrAP1 TnF receptor-associated protein 1 TnF type I receptor
IPI00030706 1 – AhSA1 AhA1, activator of heat shock 90kDa protein  
ATPase homolog 1 (yeast)
hsp90 co-chaperone
IPI00032140 2 – SerPInh1 serpin peptidase inhibitor, clade h (heat 
shock  
protein 47), member 1, (collagen binding protein 1)
collagen specific 
chaperone
IPI00220362 1 – hSPe1 heat shock 10kDa protein 1 (chaperonin 10) mitochondriaI 
chaperone
IPI0Q290566 1 TcP1 t-complex 1 chaperone
IPI00304925 2 – hSPA1A heat shock 70kDa protein 1A chaperone
IPI003g2470 2 2 hSP90AA1 heat shock protein 90kDa alpha (cytcsolic),  
class A member 1
chaperone
IPI007g4154 3 1 hSPD1 heat shock 60kDa protein 1 (chaperonin) chaperone
Ribosomal proteins
IPI00007144 1 – rPL26L1 ribosomal protein L26-like 1 ribosomal protein
IPI00008530 1 – rPLP0 ribosomal protein, large, P0
IPI00011253 2 – rPS3 ribosomal protein S3
(Continued)Vishal et al
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Table 1. (Continued)
ID control 17AAG Gene Function
Ribosomal proteins
IPI00012772 1 – rPLg ribosomal protein L8
IPI00013415 1 – rPS7 ribosomal protein S7
IPI00013917 1 – rPS12 ribosomal protein ribosomal proteins
IPI00024933 1 – rPL12 ribosomal protein L12
IPI00025091 1 – rPS11 ribosomal protein S11
IPI00026271 1 – rPS14 ribosomal protein S14
IPI00027270 1 – rPL26 ribosomal protein L26
IPI00179330 – 2 rPS27A ribosomal protein S27a
IPI00216587 2 – rPS8 ribosomal protein S8
IPI00217030 2 – rPS4X ribosomal protein S4, X-linked
IPI00219153 2 – rPL22 ribosomal protein L22
IPI00221092 3 – rPS16 ribosomal protein S16
IPI00247583 2 – rPL21 ribosomal protein L21
IPI00299573 1 – rPL7A ribosomal protein L7a
IPI00376798 2 – rPL11 ribosomal protein L11
IPI004a6758 1 – rPL27A ribosomal protein L27a
IPI00550021 1 – rPL3 ribosomal protein L3
Mitochondrial metabolic proteins
IPI00000874 3 – PrDX1 peroxiredoxin 1 metabolic enzyme
IPI00000877 3 1 hYOU1 hypoxia up-regulated 1 transritpion factor
IPIOD003348 2 – gnB2 guanine nucleotide binding  
protein (g protein), beta polypeptide 2
g-protein
IPI00005158 1 – LOnP1 Ion peptidase 1, mitochondrial Mitochondrial protein 
degradation
IPI00006482 1 – ATP1A1 ATPase, na+/K+ transporting, alpha 1 
polypeptide
ATPase transporter, 
maintains 
electrochemical
IPI00007084 1 – SLc25A13 solute carrier family 25, member 13 (citrin) aspartate glutamate 
carrier
IPI00007611 4 – ATP5O ATP synthase, h+ transporting, mitochondrial F1 Transmission and 
proton  
conductance
IPI00008167 1 – ATP1B3 ATPase, na+/K+ transporting, beta 3 ATPase protein involved 
in  
na/K transport
IPI00008524 1 – PABPc1 poly(A) binding protein, cytoplasmic 1 mrnA metabolism
IPI00008982 1 – ALDh18A1 aldehyde dehydrogenase 18 family. 
memberAI
amino acid metabolism
IPID0009030 1 – LAMP2 lysosomal-associated membrane protein 2 autophagy
IPI00009904 5 – PDIA4 protein disulfide isomerase family A, member 4 Catalysis of disulfide 
bonds
IPI00011937 3 – PrDX4 peroxiredexin 4 redox-regulation
IPI00013847 1 – UQcrc1 ubiquinol-cytochrome c reductase core  
protein I
respiratory chain 
complex
IPI00017726 1 – hSD17B10 hydroxysteroid (17-beta) dehydrogenase 10 dehydrogenesase
IPI00020599 5 1 cALr calreticulin calcium binding 
chaperone
IPI00021766 2 – PTM4 reticij Ion 4 Mitochondrial 
sequestration to er
(Continued)17AAg induces mitochondrial deformity
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Table 1. (Continued)
ID control 17AAG Gene Function
Mitochondrial metabolic proteins
IPI0D022793 1 – hADhB hydroxyacyl-coA dehydrogenase/ 
3-ketoacyl-coA thiolase/enoyl-coA hydratase 
(trifunctional protein), beta subunit
Lipid metabolism and  
fatty acid oxidation
IPI00022810 1 cTSc cathepsin c calcium protease
IPI00022462 – 1 TFrc transferrin receptor (p90, cD71) receptor
IPI00024067 2 cLTc clathrin, heavy chain (hc) Vesicular protein
IPI00025252 3 1 PDA13 protein disulfide isomerase family A, member 3 catalysis of disulfide 
bonds  
in proteins
IPI00025796 1 – nDUFS3 nADh dehydrogenase (ubiquinone) Fe-S 
protein 3, 30kDa fnADh-coenzvme Q reductase)
Oxidative 
phosphorylation
IPI00025874 1 rPn1 ribophorin I Oligosaccharide 
catalysis
IPI00027350 1 PrDX2 peroxiredoxin 2 redox-regulation
IPI00027462 – 1 S100A9 S100 calcium binding protein A9 calcium protein
IPI0OD29133 1 – ATP5F1 ATP synthase, h+ transporting, mitochondrial 
Fo
ATP synthase complex
IPI00030255 2 – PLOD3 procollagen-lysine, 2-oxoglutarate  
S-dioxygenase 3
collagen cross-linking
IPI00030275 – 1 TrAP1 TnF receptor-associated protein 1 TnF type I receptor
IPI00031522 1 – hADhA hydroxyacyl-coA dehydrogenase/ 
3-ketoacyl-coA thiolase/enoyl-coA hydratase 
(trifunctional protein), alpha subunit
dehydrogenease
IPI00032140 2 – SerPInhl serpin peptidase inhibitor, clade h  
(heat shook protein 47), member 1, (collagen  
binding protein 1)
Collagen specific 
chaperone
IPI00032903 2 – PTrh2 peptidyl-trnA hydrolase Promotes casapse  
independent apoptosis
IPI00075248 1 – calmodulin calcium binding protein
IPI00152540 2 – cD109 cD109 molecule glycophosphatidyl-
inositol  
linked cell surface 
antigen
IPI00179330 2 – ArF1 ADP-ribosylation factor 1 Protein trafficking
IPI00215948 1 – cTnnA1 catenin (cadherin-associated protein),  
alpha 1,102kDa
adhesion protein
IPI00217906 2 – gnAI2 guanine nucleotide binding protein  
(g protein), alpha inhibiting
g-protein
IPI00218918 2 – AnXA1 annexin A1 ca2+ binding protein;  
involved in exocytosis
IPI00219018 e 2 gAPDh glyceraldehyde-3-phosphate glycolosis
IPI00219219 2 – LgALS1 lectin, galactoside-binding, soluble, 1 regulate cell 
proliferation,
IPIDD220578 1 – gnAI3 guanine nucleotide binding protein  
(g protein), alpha inhibiting
g-protein
IPI00220644 1 – PKM2 pyruvate kinase, muscle glycolosis
IPI00291006 4 – MDh2 malate dehydrogenase 2, nAD (mitochondrial) oxidoreductase
IPIDD299571 1 2 PDIA6 protein disulfide isomerase family A,  
member 6
catalysis of disulfide 
bonds  
in proteins
IPI00303476 15 1 ATP5B ATP synthase, h+ transporting,  
mitochondrial F1 complex, beta polypeptide
ATP synthase
(Continued)Vishal et al
28  Drug Target Insights 2011:5
teins, whereas the up-regulated proteins were Ras-like 
GTPases, peptidyl prolyl isomerases and transposases 
(Table 2). Hsp90 is known to interact with ATPase 
family  of  proteins,  however,  its  association  with 
GTPase family of proteins was found limited.1,47
Discussion
There  is  growing  evidence  that  mitochondria  are 
potential targets to fight against cancer and various 
other pathological disorders.48 Pharmacological inhi-
bition of Hsp90 has also emerged as a novel strat-
egy to combat cancer since Hsp90 inhibition induces 
tumor  selective  combinatorial  attack  on  multiple 
signaling molecules.25 Hsp90 inhibition is also con-
nected in inhibiting mitochondria-initiated apoptosis. 
New  class  of  drugs  such  as  mitochondria-directed 
Hsp90  antagonists  provided  information  on  how 
Hsp90 regulates mitochondria.49,50 Like cytoplasmic 
chaperones,  mitochondrial  chaperones  were  also 
associated in regulating protein folding and unfold-
ing  mechanisms  to  preserve  mitochondrial  protein 
homeostasis.51 However, Hsp90 inhibition effects on 
mitochondrial  organization  are  largely  not  known. 
From  the  present  study,  we  display  that  the  treat-
ment  of  tumor  cells  with  17AAG  alone  induces 
mitochondrial dysfunction. From the kinetic studies, 
we  showed  that  mitochondrial  destabilization  was 
an early step of Hsp90 inhibition, and was because 
of  increased  mitochondria  elongation  and  matrix 
vacuolization.
From the biochemical analysis, we showed that 
17AAG  induces  ex  vivo  mitochondrial  swelling, 
a  change  in  ∆Ψm,  mitochondrial  elongation  and 
  vacuolization. The differential response of 17AAG 
in isolated mitochondria (ex vivo) from the in vivo 
effects may argue with the selective targeting. The 
sucrose gradient has shown to improve mitochondria 
integrity in isolated mitochondria. However, multiple 
reports show that the concentrations above 20 mM 
are suitable but not enough to improve mitochondrial 
integrity,  suggesting  that  mitochondria  isolations 
despite care can still affect its integrity. The effect on 
cytochorme c release may be a combined effect of 
17AAG with in vitro mitochondria isolation proce-
dure. Isolated mitochondria are lacking their associa-
tion with cytoskeletal and cytoplasmic constituents, 
thus cannot mimic exact in vivo condition. This could 
be one reason why we see a different response in iso-
lated mitochondria, which therefore may not be related 
to the effect of 17AAG. Because of the limits imposed 
Table 1. (Continued)
ID control 17AAG Gene Function
Mitochondrial metabolic proteins
IPIDD395769 1 – ATP5c1 ATP synthase, h+ transporting,  
mitochondrial F1
Oxidative 
phosphorylatior
IPI00396321 – 1 Lrrc59 leucine rich repeat containing 59 potential transcription 
factor
IPI00418169 3 – AnXA2 annexin A2 Sensitize cells to 
apoptosis
IPI00418262 1 – ALDOc aldolase c, fructose-bisphosphate glyco lysis
IPI00419585 1 – PPIA peptidylprolyl isomerase A (cyclophilinA) isomarase
IPI00440493 5 2 ATP5A1 ATP synthase, h+ transporting,  
mitochondrial F1
Oxidative 
phosphorylation
IPI00465273 1 – UhrF1BP1 UhrF1 binding protein 1 Ubiquitin ligase
IPI00465439 4 – ALDOA aldolase A, fructose-bisphosphate Aldolase
IPI00646304 8 – PPIB peptidylprolyl isomerase B (cyclophilin B) Isomerase
IPI00783271 1 – LrPPrc leucine-rich PPr-motif containing  
[homo sapiens]
rnA metabolism
IPI0O848226 2 – gnB2L1 guanine nucleotide binding protein  
(g protein), beta polypeptide
g-protein
IPI00884105 – 1 LAMP1 lysosomal-associated membrane protein 1 Autophagy
IPI00914848 1 – SerPIne2 serpin peptidase inhibitor clade e  
(nexin, plasmincgen activator)
Peptidase17AAg induces mitochondrial deformity
Drug Target Insights 2011:5  29
Table 2. The identified unmapped peptides showing gene ID and classification.
Up regulated proteins
protein ID peptide sequence Mass Xcor protein name
IPI00000875 r.VLSAPPhFhFgQTnr.T 1708 3.304
IPI00000875 K.STFVLDeFKr.K 1242 2.305
IPI00000875 K.AKDPFAhLPKS 1124 2.281 elongation factor gamma-1
IPI00010397 r.YFYhQeeYVr.F 1434 2.817 Mhc class II antigen
IP 00025447 K.YYVTIIDAPghr.D 1405 3.131 elongation factor alpha-1
IPI00025447 r.VeTgVLKPgM*TWTFA  
PVnVTTeVK.S
2531 2.846 (putataive conserved domain)
IPI00026154 K.AQQeQeLAADAFK.e 1449 4.052 beta galactosidase 2 subunit and protein kinase
IP 100026154 K.LWeeQLAAAK.A 1159 2.9 c
IPI00045921 r.TAgTLFgegFr.A 1156 2.621 ATPase family: AAA containing domain
IP 100166768 K.TIgggDDSFnTFFSe  
TgAgK.h
2008 4.856 tubulin alpha chain-1
IPI00168703 r.TcLWnDQLYLVggFg 
eOgrTASPQVcILDFI
3431 3.422 ankyryn/kelch interacting protein
IPI00176692 r.gFAFVTFDDhDSVDK.I 1700 3.824 heterogenous nuclear ribonuclearprotein A1-like
IPI00334627 r.TnQeLQeInr.V 1245 3.215 annexin A2
IPI00386208 K.AIgLWPSLTgK.L 1155 2.407 gtucose-6-phosphate dehydrogenase
IPI00382990 r KInIegQeLVenegr L 1728 4 159 transposase
IPI00444262 K.nDLAWDVr.I 1001 2.926
IPI00444262 K.eVFeDAAeIr.L 1179 2.246 nucleolin and its isoforms
IPI00451941 M-LWeVAngrSLVWgA  
eAVQALr.e
2484 2.203 endonuclease subunit Sen34-like isoform
IPI00555874 K.IWhhTFYKeVr.V 1516 2.614 actin
IPI00915898 r.TQePQgTQLAPr.A 1326 2.373 hypothetical protein with homology with  
multiple cellular helix, cSF and etc
Down regulated proteins
IP I00005180 r.hnYgVgeSFTVQr.r 1494 3.756 Mhc class II antigen
IP100006180 r.FDSDVgeYr.A 1087 2.387
1PI00005719 r.FADDTYTeSYISTIgVDFK.I 2172 4.742 ras like gTPase  
(putative conserved domain)
IPI00005719 K.nATnVeQSFMTM’AA eIK.K 1901 3.855
IP 00005719 K.nATnVeQSFM-TMAA eIK.K 1901 3.61
IPI00005719 K.eFADSLgIPFLeTSAK. n 1725 3.158
IPI00005719 K.LLLIgDSgVgK.S 1072 2.719
IPI00027851 r.hYLPLSSILDTLDVM*AYnK.L2209 3.294 hexoseaminidase
IPI00382990 r.KInIegQeLVenegr.L 1728 4.159 transposase
IPI00419585 K.FeDenFILK.h 1155 2.604 PPIA peptidylprolyl isomerase A  
(cyclophilin A)
IPI00917434 r.ADghPghcSLM*MLh 
LLQLgVWK.r
2459 2.341 secreted transmembrane protein:  
TrAP decarboxvlase
on isolation procedures to get intact mitochondria, 
we have not used isolated mitochondria in evaluating 
drug effects in our following experiments. However, 
the analysis of mitochondria from intact cells using 
different anti-Hsp90 drugs confirmed that indeed it is 
Hsp90 inhibition that caused a change in mitochon-
drial destabilization.
Mitochondria forms interconnected networks within 
the  cell,22  and  they  reach  equilibrium  between  two 
states in healthy cells by regulating the relative rates 
of organelle fusion and fission.52 Our data suggested 
fusion of mitochondria as observed from micrographs. 
However, the electrograph data suggested that 17AAG 
treatment induced both elongation and engorgement of Vishal et al
30  Drug Target Insights 2011:5
mitochondria. More interestingly, the early deformity 
noted  in  different  chemotherapeutic  treatments  sug-
gested  that  only  Hsp90  inhibition  induced  such 
deformity.
A drop in mitochondrial membrane potential occurs 
when there is advancing apoptosis with release of 
cytochrome c into the cytosol. However, in our study, 
we see no cytochrome c release but a change in mem-
brane order suggesting a direct effect of the drug on 
mitochondrial membrane. Earlier it has shown that 
Hsp90 inhibitor, geldanamycin affects plasma mem-
brane  integrity  when  used  in  higher  concentrations 
(18  µM).  However,  information  on  drug  induced 
effects  on  mitochondrial  membrane  is  scanty  and 
therefore needs future   studies. Since cholesterol-rich 
membrane  micro  domains  are  rich  with  signaling 
complexes, we have confirmed with our preliminary 
experiments that Hsp90 also localizes to such regions 
on  plasma  membrane  (unpublished  observations). 
Digitonin may be helping in the sensitization of such 
domains for 17AAG intake.
While many roles of mitochondria are common to 
different cells, a recent proteomic survey suggested 
that  about  half  of  the  mitochondrial  proteins  are 
tissue-specific and may reflect on diversity in mito-
chondrial architecture.54 Although we could get large 
information on time-dependent mitochondrial elon-
gation induced by 17AAG at 6 h and 12 h, a decrease 
in mitochondria length by 24 h was found to be inter-
esting. Mitochondrial proteomics offer a great under-
standing of mitochondrial roles.55 Our studies though 
provided gross information on how 17AAG affected 
the mitochondrial integrity and deformity, they did 
not provide any information on molecular and pro-
tein networks that were affected by the treatment. 
The most direct approach for studying the mitochon-
drial proteome is to purify mitochondria from cells 
and identify proteins using mass spectrometry (MS). 
Most  widely  used  mitochondrial  proteomics  are 
through 2-DE which separates proteins   according to 
  isoelectric points (pI). However, 2-DE suffers from 
the disadvantage that majority of mitochondrial pro-
teins  are  hydrophobic,  low  molecular  weight  and 
basic proteins, which cannot be resolved56. There-
fore, in the present study, we have adapted 1D PAGE 
LC MS/MS to study mitochondrial proteomics. From 
our MS analysis, we report that 17AAG treatment 
massively affected mitochondrial proteins resulting 
in 61% loss of mitochondrial proteins compared to 
the control. Hsp90 being a sticky protein is known to 
associate with several cellular proteins.3 In addition 
to  disassociation  of  chaperone  complex  proteins, 
inhibition of Hsp90 inhibits its association with sev-
eral  client proteins,  which  might have resulted in 
destabilized protein complexes and therefore could 
have resulted in severe protein loss.
Our MS analysis provided insights to the mito-
chondrial  proteins  that  were  targeted  by  17AAG 
treatment. The different groups of proteins affected 
by 17AAG include chaperones, metabolic enzymes, 
oncogenes and nucleic acid ingredients. The analy-
sis of these groups has not provided clues for desta-
bilization of mitochondria. However, novel groups 
of unmapped proteins especially the GTPase family 
of proteins which contained reputed peptide signa-
tures suggested possible role of these GTPases in 
mitochondria stabilization.57 Our results appeared 
to  be  contrasting  with  Margineantu  et  al  (2007) 
who  showed  accumulation  of  mitochondrial  pro-
teins,  we  report  early  mitochondrial  deformity. 
Further, they used lower concentrations of 17AAG 
(0.4 µM) with prolonged incubation time (24 h) for 
their study, whereas, in the present study, we used 
2.0 µM 17AAG and the early mitochondrial effects 
we reported were by 6 h of 17AAG treatment. Since 
Hsp90 and Hsp70 chaperones were involved in the 
import and export of proteins to mitochondria, the 
inhibition of Hsp90 chaperone limited the import 
and export, this would have accumulated proteins 
in the mitochondria. Accumulation of proteins does 
not always infer role, but reflects on increased pro-
teotoxicity. Since low doses of chemotherapeutic 
agents  show  either  delayed  cellular  response  or 
recovery  from  drug-induced  cellular  effects,  the 
direct effect on mitochondria after 24 h would be 
an  outcome  of  inhibition  of  several  biochemical 
events.
In summary, we examined Hsp90 inhibition effects 
on  three  tumor  cells  types;  HeLa,  HNGC2,  and 
IMR-32. Our data displays that Hsp90 inhibition first 
targets mitochondria in three different cell types, there-
fore 17AAG-induced cellular effects were not cell 
type  specific.  Further  using  different  anti-Hsp90 
drugs in comparison with nonHsp90 drugs, we dem-
onstrated that 17AAG effects were not drug specific, 
but Hsp90 inhibition specific. From our study, we 17AAg induces mitochondrial deformity
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clearly show that Hsp90 inhibition by itself affects 
the  mitochondrial  integrity  inducing  its  deformity, 
which subsequently leads to the loss of mitochondrial 
proteins. Since Hsp90 has been identified as a poten-
tial biomarker to target cancer and 17AAG is already 
in the clinical evaluation to treat cancer, our findings 
may gain utmost importance in anticancer treatment 
studies using anti-Hsp90 inhibitors.
Abbreviations used in this paper
17AAG, 17-allylamino-17-demethoxygeldanamycin; 
Hsp90, heat shock protein 90; MPT, mitochondrial 
permeability  transition;  ∆Ψm,  mitochondrial  inner 
membrane potential; DiOC6(3), 3, 3’-dihexyloxacar-
bocyanine iodide; CCCP, Carbonyl cyanide m-chlo-
rophenylhydrazone;  CsA,  cyclosporine  A;  JC-1, 
5,5’,6,6’-tetrachloro-1,1’3,3’-tetraethylbenzimida-
zolylcarbocyanin  iodide;  DAPI,  4’-6-Diamidino-2-
phenylindole.
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